Exhibit 99.1



FOR IMMEDIATE RELEASE:

                  GERALD MOORE APPOINTED ABMC PRESIDENT AND CEO
                  ---------------------------------------------
            Company Chairman Had Assumed Acting CEO Responsibilities
                          from Robert L. Aromando Jr.

KINDERHOOK, NY, February 7, 2002 - American Bio Medica Corporation (NASDAQ:
ABMC) today announced that its board of directors has officially appointed
Gerald Moore president and chief executive officer. Moore succeeded Robert L.
Aromando Jr. as acting president and CEO when Aromando requested a leave of
absence in December 2001. Aromando officially resigned his positions January 31,
2002. Moore was appointed president and CEO by a unanimous vote of the ABMC
board during a board meeting yesterday.

Aromando remains an ABMC director and consultant for strategic business
development. Moore also retains his position as chairman of the ABMC board of
directors.

"This is a seamless transition, one that allows me to focus attention on
managing ABMC with full authority, and also allows Bob Aromando to remain
affiliated with the company, but focus most of his attention on the matters for
which he requested a leave," said Moore. "I am grateful for this opportunity and
am quite optimistic about ABMC's future."

Moore brings prior experience as a chief executive to ABMC, as well as an
extensive background in international health care marketing and sales.

He was most recently president and CEO of Med-Ox Diagnostics of Canada, and
president of BioSys, Inc. From 1990 until 1998, Moore was president of UNIPATH
(North America), a division of worldwide food, home care and personal care
conglomerate Unilever. Under Moore's leadership UNIPATH became a preeminent
leader in the clinical health care markets in Canada and the United States.

Moore is a member of the board of directors of the Canadian Association of
Clinical Microbiology and Infectious Diseases (CACMID), a director of the
Canadian Clinical Standards organization and he serves on the liaison board of
exhibitors to the Interscience Conference on Antimicrobial Agents and
Chemotherapy (ICAAC) of the American Society of Microbiology. Moore earned a
degree in chemistry and mathematics from Strathclyde University in Glasgow,
Scotland, in 1961.

In his first conference call with ABMC investors in December, Moore outlined his
priorities for managing ABMC -- specifically, developing strategic business in
the workplace and clinical markets, creating new products and streamlining
operations. Since Moore has become acting president and chief executive officer,
ABMC has announced that it has entered into a distribution agreement with Quest
Diagnostics, Inc. (NYSE:DGX), making ABMC Quest Diagnostics' exclusive
manufacturer of urine based point-of collection drug testing devices, earned
preferred vendor status with Express Personnel and applied for FDA clearance of
its proprietary on-site drug test for Oxycodone.

                                     (more)






About American Bio Medica Corporation

American Bio Medica Corporation develops, manufactures and markets inexpensive,
accurate, on-site drugs-of-abuse diagnostic kits, sprays and support services
worldwide. The company's global distributors target the workplace, physicians,
corrections, clinical, and educational markets. ABMC's Rapid Drug Screen(R) and
OralStat6(TM) test for the presence or absence of drugs of abuse in urine and
saliva, respectively, while its Drug Detector(TM) identifies minute traces of
illegal drugs on surfaces. ABMC was recently listed among the top ten
biotechnology companies on the Deloitte & Touche 2001 Technology Fast 500, a
ranking of the fastest growing companies in North America.

Forward-looking statements in this release are made pursuant to the "safe
harbor" provisions of the Private Securities Litigation Reform Act of 1995.
Investors are cautioned that such forward-looking statements involve risk and
uncertainties, including without limitation, continued acceptance of the
Company's products, increased levels of competition for the Company, new
products and technological changes, intellectual property rights and other risks
detailed from time to time in the Company's periodic reports filed with the
Securities and Exchange Commission.



                                      # # #